 |
 |

Genetic Markers of Head and Neck Cancer
Identifying New Molecular Targets
Arch Otolaryngol Head Neck Surg. 2003;129:366-367.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Dr Friedlander has done an elegant and realistic review of the present utility of genetic markers in the clinical care of patients with head and neck cancer. Clearly, no marker for HNSCC has been identified analogous to prostate-specific antigen for prostate cancer. In truth, there is no evidence to date that such a specific marker for head and neck cancer or SCC in general even exists. There are several reasons for this fact. First, biomarker studies are exceedingly complex and require analysis of large homogeneous study populations. Additionally, head and neck cancers are heterogeneous biologically as well as clinicopathologically. For example, different genes may be implicated in tonsil cancer than in larynx cancer, or different genes may be involved in tumors arising in nonsmokers than those in smokers.
Figure appears in full text version.
|
|
|
|
|
However, some progress has been made on the front of prognostic markers for outcome in head and neck . . . [Full Text of this Article]
RELATED ARTICLES
The Use of Genetic Markers in the Clinical Care of Patients With Head and Neck Cancer
Paul L. Friedlander
Arch Otolaryngol Head Neck Surg. 2003;129(3):363-366.
EXTRACT
| FULL TEXT
Genetic Markers in the Clinical Care of Head and Neck Cancer: Slow in Coming
Wayne Koch
Arch Otolaryngol Head Neck Surg. 2003;129(3):367-368.
EXTRACT
| FULL TEXT
|